Working… Menu

A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV Institute (Maximus)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00811616
Recruitment Status : Completed
First Posted : December 19, 2008
Last Update Posted : May 11, 2010
Information provided by:
Sahajanand Medical Technologies Pvt. Ltd.

Brief Summary:


The primary objective of this study is to assess the safety and efficacy of the Supralimus - Core™ Sirolimus Eluting Stent in de novo native vessel obstructive coronary artery disease.


This is a single centre, prospective study. Approximately 105 patients were enrolled in the study. Patients were followed for twelve months post-procedure. All patients were to have a repeat angiography at 8 months.


The study population consisted of approximately 105 patients with de novo native vessel obstructive coronary artery disease with no specific criteria. Patients from the daily practice were included. Patients had to meet all eligibility criteria for inclusion into the study.


The primary safety endpoint of the study is defined as Major Adverse Cardiac Events (MACE) at 30 days.

The primary efficacy endpoint is the in-stent binary restenosis rate at 8-month follow-up determined by off-line Quantitative Coronary Angiography.

The following secondary efficacy endpoints were assessed

  • Angiographic success
  • Procedure success
  • Quantitative Coronary Angiography derived vessel parameters in-stent and 5 mm proximal and 5 mm distal from the edge of the stent: acute gain, MLD, % DS, late loss, mean diameter. In-stent pre-, post and at 8-month follow-up.
  • Clinically justified Target Lesion Revascularization (TLR) at 12 months

The following secondary safety endpoints were assessed:

  • MACE until 12 months
  • Device related SAEs until 12 months
  • Angiographic stent thrombosis: Subacute (after procedure until 30 days) and Late (after 30 days until 12 months)

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: Supralimus-Core™ Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 105 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety And Efficacy Evaluation of Sirolimus Eluting Supralimus-Core™ Stent at MAX DDHV Institute in the Treatment of de Novo Native Coronary Artery Lesions
Study Start Date : July 2006
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Sirolimus

Intervention Details:
  • Device: Supralimus-Core™
    Sirolimus Eluting Cobalt Chromium based coronary stent system

Primary Outcome Measures :
  1. Primary safety endpoint: Major Adverse Cardiac Events (MACE) [ Time Frame: 30 days ]
  2. Primary efficacy endpoint: In-stent binary restenosis rate determined by off-line Quantitative Coronary Angiography. [ Time Frame: 8 Month ]

Secondary Outcome Measures :
  1. Secondary safety endpoints: - MACE until 12 months, Device related SAEs until 12 months, Angiographic stent thrombosis: Subacute (after procedure until 30 days) and Late (after 30 days until 12 months)
  2. Secondary efficacy endpoints: Angiographic, Procedure success; acute gain, MLD, % DS, LL, mean diameter; In-stent pre-,post,8-month follow-up; Clinically justified TLR at 12 months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient must be >= 18 years of age;
  • Symptomatic ischemic heart disease (CCS class 1 -4 , Braunwald class IB, IC, IIB, IIC, IIIB,IIIC) and/or objective evidence of myocardial ischemia;
  • Vessel size of >= 2.5 and <= 3.5mm.
  • Target lesions which can be covered by stent in a manner lesion stent ratio of at least 1.5.
  • Acceptable candidate for coronary artery bypass surgery (CABG);
  • Target lesion stenosis is >50% and <100% (TIMI flow I) (visual estimate);
  • The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB).

Exclusion Criteria:

  • Women of childbearing potential;
  • Impaired renal function (creatinine > 2.0 mg/dl or 177 µmol/l);
  • Any patient who has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis);
  • Recipient of heart transplant;
  • Restenotic or lesion in graft.
  • Patient with a life expectancy less than 12 months;
  • Known allergies to aspirin, clopidogrel bisulphate (Plavix), ticlopidine (Ticlid), heparin or stainless steel;
  • Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
  • Currently participating in an investigational drug or another device study, or subject to inclusion in another investigational drug or another device study during follow-up.

Angiographic Exclusion criteria:

  • Unprotected left main coronary artery disease with >=50% stenosis;
  • Angiographic evidence of thrombus (thrombus larger than half the diameter of the vessel and/or requiring other interventions such as angiojet, exciser, thrombolysis, etc.);
  • Ejection fraction <= 30%;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00811616

Layout table for location information
Max Heart and Vascular Institute
New Delhi, India, 110017
Sponsors and Collaborators
Sahajanand Medical Technologies Pvt. Ltd.
Layout table for investigator information
Principal Investigator: Dr. Ashok Seth Escorts Heart Institute & Research Centre

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mr. J.P. Dutta, Sahajanand Medical Technologies Pvt. Ltd Identifier: NCT00811616     History of Changes
Other Study ID Numbers: The MAXIMUS study
First Posted: December 19, 2008    Key Record Dates
Last Update Posted: May 11, 2010
Last Verified: May 2010
Keywords provided by Sahajanand Medical Technologies Pvt. Ltd.:
Coronary artery disease
de novo native coronary artery lesion
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs